SecBot SecBot

INCR

Intercure Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. L3· CIK 0001857030 Biotech & Drug Discovery
$4.27 −0.26 (−5.74%)
Oct 26 4:00 PM ET · prev $4.53
Market cap
$66.6M
Micro cap
1 year
−41.9%
from $7.35 · Oct 27
30 days
−16.1%
from $5.09
52-week range
$3.65–7.35
−42% from high · low Mar 25
Avg volume 20D
4.0K
shares / day
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
Filing reports
5
analyzed by SecBot
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2
Strongest BULLISH InterCure finalized a NIS 230M (~$77M) settlement with Israeli authorities for war-related indirect damages…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • TrendDOWNTREND

    17% below its 50-day average.

Who's buying

13F
Top holderSharesValue
ROYAL BANK OF CANADA196$0.00
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND212,500$325.1K
CITADEL ADVISORS LLC107,913$118.7K
RENAISSANCE TECHNOLOGIES LLC57,800$63.6K
BlackRock, Inc.20,500$22.6K
GEODE CAPITAL MANAGEMENT, LLC20,357$22.4K
Atria Investments, Inc11,957$13.2K
MORGAN STANLEY4,082$4.5K

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 8, 2026 Listing status
Listing Status: INCR — Normal (was Deficient)
Intercure Ltd. - ordinary shares | Nasdaq Financial Status Indicator D → N
Aug 24, 2026 SEC
InterCure finalized a NIS 230M (~$77M) settlement with Israeli authorities for war-related indirect damages from the…
6-K — Impact 7/10
Aug 4, 2026 SEC
No summary provided
6-K — Impact 5/10
Jun 15, 2026 SEC
InterCure completed the first tranche of its Botanico acquisition, issuing 2.47M shares (with another 2.47M to…
6-K — Impact 5/10
Jun 9, 2026 Insider
Cohen Amos was granted 590,000 shares
Chief Financial Officer

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 9, 2026
Cohen Amos
Chief Financial Officer
AWARD590,000 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Aug 24, 2026Volatility PauseResumed
Aug 21, 2026Resumption ScheduledResumed
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 8, 2026
Listing
Listing Status: INCR — Normal (was Deficient)
Intercure Ltd. - ordinary shares | Nasdaq Financial Status Indicator D → N
Sep 8, 2026
Delisting
InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
NEW YORK and HERZLIYA, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”)…
Aug 24, 2026
Trading halt
Halt Resumed: INCR — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-08-24T13:32:26.000Z | Resumed 2026-08-24T13:37:26.000Z
Aug 24, 2026
Trading halt
Trading Halt: INCR — LUDP (Volatility Trading Pause)
Intercure Ltd. Os | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Aug 24, 2026
Trading halt
Halt Resumed: INCR — trading resumed after T3 (News and Resumption Times)
Halted 2026-08-21T23:50:00.000Z | Resumed 2026-08-24T13:00:00.000Z

SecBot reports

5 filings · 1 bullish · 1 bearish · 2 mixed · 1 neutral
All INCR filing & press-release reports (5)